tirzepatide surmount-1 weight loss percent nejm 2022 Semaglutide vs. Tirzepatide: Which GLP-1 Wins? Zepbound Clinical Trial Results: SURMOUNT-1

The pool containing Arg 34 GLP-1 (7-37) and various impurities was diluted with three volumes of water, and 40 ml of the resulting solution was applied to a 20 ml Source 15Q (Amersham Pharmacia Biotech) column equilibrated with 100ml20 mM Tris-hydroxymethyl amino-methane, pH 8.5

Tirzepatide is a dual agonist of both the glucagon receptor and the glucagon-like peptide-1 receptor (GLP-1 RA)

Tirzepatide has demonstrated remarkable weight loss outcomes in clinical trials, with participants losing up to 22% of body weight at higher maintenance doses

Participants receiving tirzepatide at maximum doses achieved average weight losses of 2022% of baseline body weight, while semaglutide trials reported 1417% reductions

The British journal of nutrition, 124(11), 11211132